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Low blood dehydroepiandrosterone sulfate (DHEAS) levels have strong positive associations with
stroke and coronary heart disease. However, it is unclear whether DHEAS is independently associated
with cardiovascular risk factors. Therefore, we examined the association between cardiovascular risk
factors and DHEAS concentration among a high-risk population of Latinos (Puerto Ricans aged 45 to
75 years at baseline) in a cross-sectional analysis of the Boston Puerto Rican Health Study. Of eligible
participants, 72% completed baseline interviews and provided blood samples. Complete data were
available for 1355 participants. Associations between cardiovascular risk factors (age, sex, total cho-
lesterol, high-density lipid cholesterol, triglycerides, and glucose) and log-transformed DHEAS (mg/dL)
were assessed. In robust multivariable regression analyses, DHEAS was significantly inversely as-
sociated with age (b = 212.4; 95% CI: 215.2, 29.7; per 5 years), being female (vs. male) (b = 246; 95%
CI: 255.3, 236.6), and plasma triglyceride concentration (b = 20.2; 95% CI: 20.3, 20.1; per 10 mg/dL)
andwas positively associatedwith total cholesterol and plasma glucose levels (b = 1.8; 95%CI: 0.6, 3 and
b = 0.2; 95%CI: 0.04, 0.3, respectively, per 10mg/dL) after adjustment for smoking, alcohol, and physical
activity and for postmenopausal hormone use in women. Estimates were unchanged after adjustment
for measures of chronic disease and inflammation. Women exhibited a stronger age-related decline in
DHEAS and a positive association with glucose in contrast to findings amongmen (Pinteraction, 0.05). In
conclusion, in this large study of Latinos with a heavy cardiovascular risk factor burden, we observed
significant associations between cardiovascular disease (CVD) risk factors and DHEAS, with variations
by sex. These findings improve our understanding of the role DHEAS may play in CVD etiology.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Puerto Ricans have the highest cardiovascular risk factor profile of US Latino heritage
groups, suggesting an elevated risk of future cardiovascular disease (CVD) morbidity and
mortality [1]. Results from theHispanic Community Health Study/Study of Latinos indicated
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that 25% of Puerto Ricans had three or more metabolic cardiovascular risk factors. For
example, 16% of men and 19% of women had diabetes, 41% of men and 51% of women were
obese, and 27% of men and 29% of women had hypertension. The Boston Puerto Rican Health
Study (BPHS) provides a unique opportunity to study dehydroepiandrosterone sulfate
(DHEAS) because of its detailed physiologic data on a large cohort of Latinos with high
cardiovascular risk. The purpose of this study was to examine the association between
DHEAS concentration and cardiovascular risk factors among Puerto Rican adults to better
understand the higher burden of CVD among Puerto Ricans.
DHEAS, produced primarily in the adrenal cortex, is the most abundant circulating
hormone in humans. Evidence suggests that low DHEAS level may be a risk factor for total
and cause-specific CVD, such as coronary heart disease [2‒4] and stroke [3, 5]. Moreover, low
DHEAS level has been associated with a greater prevalence and incidence of cardiometabolic
risk factors (high blood pressure, insulin resistance, and impaired fasting glucose level),
which are highly prevalent among particular Latino heritage groups such as Puerto Ricans
[6‒9].
Animal and humanmodels support amechanistic role for DHEAS in CVD pathophysiology
through its influence on vasodilation and blood pressure [10, 11], glucosemetabolism [12, 13],
triglyceride (TG) concentration, and endothelial dysfunction [14]. However, with few ex-
ceptions, associations between cardiovascular risk factors and DHEAS have generally been
examined in studies with statistical adjustment limited to demographic factors (i.e., sex and
age) [15‒18]. Furthermore, DHEAS may vary by race/ethnicity [6‒9]; however, few data are
available for Latinos [6, 7]. Moreover, we are unaware of any studies that have evaluated
associations between cardiovascular risk factors and DHEAS concentration among Latinos.
Therefore, we hypothesized that adverse cardiovascular risk factors would be associated with
lower DHEAS concentration.
1. Materials and Methods
A. The BPHS
The BPHS is an ongoing prospective cohort study initiated to examine the association be-
tween psychosocial stress, allostatic load, and systemic health (e.g., depression, disability,
cognitive impairment, and metabolic conditions). Details of the study design were previously
described in detail [19]. Briefly, 1500 self-identified Puerto Ricans aged 45 to 75 years who
were living in the Boston, Massachusetts, metropolitan area and were able to answer
questions in either English or Spanish were enrolled between 2004 and 2009. Participants
were recruited using door-to-door enumeration based on census track data and community
outreach. All data were collected through in-home assessments, consisting of interviewer-
administered questionnaires and examinations by trained bilingual staff. Participants were
compensated $50 for their time. Baseline questionnaires included questions on demographic,
socioeconomic, psychosocial and behavioral factors, medical history, cognitive function,
physical disability, medication use, diet, and acculturation. Anthropometric and blood
pressuremeasurements were obtained during the interview process, with biomarker samples
obtained the following day in the morning or as soon as possible thereafter. Follow-up as-
sessments were conducted 2 and 5 years later; however, the analyses presented herein are
restricted to baseline data [19]. The analytic sample included 1450 participants with baseline
DHEAS measurement.
B. Blood Sample Assay
Detailed information on blood sample assays was previously described [19]. Briefly, 12-hour
fasting blood draws were conducted in the home by a certified phlebotomist on the morning of
the day following the home interview. On average, blood samples were collected at 08:18 6
1.23 hours (median = 08:15 hours; interquartile range, 07:15 to 09:22 hours). Blood samples
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were carried back to the Nutrition Evaluation Laboratory at the Human Nutrition Research
Center on Aging at Tufts University (Boston, MA) on the day of collection in coolers equipped
with dry ice and were inventoried according to standard protocol. Samples were immediately
cooled to 4°C, and plasma and serum were separated within 4 hours in a refrigerated
centrifuge. Aliquots were saved in 1-mL cryogenic, screw-cap tubes and stored at 270°C for
later processing.
Serum DHEAS concentration (mg/dL) was measured by solid-phase two-site chemilumi-
nescent immunometric assay using the Immulite 1000 DHEA-S kit (LKDS1; Siemens
Medical Solutions Diagnostics, Los Angeles, CA) [20], with a mean intra-assay coefficient of
variation of 6.8% to 9.5%. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), and
TGs were analyzed from EDTA plasma using standard laboratory assays [19]. Low-density
lipoprotein cholesterol and very-low-density lipoprotein (VLDL) were calculated as VLDL =
TGs/5; low-density lipoprotein cholesterol = total cholesterol 2 (VLDL + high-density lipo-
protein). Serum high-sensitivity C-reactive protein (CRP) and insulin levels were measured
with a solid-phase, two-site chemiluminescent immunometric assay (Immulite 1000 High
Sensitive CRP Kit [21] and Insulin Kit [22], respectively; Siemens Medical Solutions Di-
agnostics). Serum glucose level was measured by enzymatic, kinetic reaction with Olympus
Glucose Reagents (OSCR6121; Olympus America Inc., Melville, NY). Glycosylated hemo-
globin (HbA1c) level was estimated by determining the ratio of HbA1c to Hb along with a
conversion factor and analyzing whole blood hemolysate by latex-enhanced immunoturbi-
metric to determine theHbA1c value. Intra-assay coefficients of variation for total cholesterol,
HDL-C, TGs, and glucose were,5%, and they were,10% for CRP (4.2% to 6.4%) and insulin
(5.2% to 6.4%).
C. Cardiovascular Risk Factors
Data on cardiovascular risk factor profiles were obtained from baseline interviewer-
administered questionnaires, clinical measurements, and blood samples. The baseline
questionnaire included demographic (sex, age), lifestyle and behavioral factors, history of
chronic disease, and medication use. The questionnaire was based on national surveys
validated in both Hispanic/Latino and elderly populations (National Health and Nutrition
Examination Survey III, the Hispanic Health and Nutrition Examination Survey, and the
National Health Interview Survey’s Supplement on Aging) [19]. Self-reported history of CVD
(yes/no) and diabetes (yes/no) and frequency and history of alcohol use (g/d) and smoking
status (never/former/current) were collected. Current physical activity was assessed using a
modified Paffenbarger questionnaire, which was previously tested in an elderly Puerto Rican
population [23, 24]. All anthropometric measures were taken in duplicate by trained in-
terviewers and were averaged for analysis. Weight was measured using a clinical scale
(Toledo Weight Plate, Model I5S; Bay State and Systems Inc., Burlington, MA), and height
was measured with a portable stadiometer. Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) levels were measured in duplicate using an electronic sphygmomanometer
(DinamapTMModel 8260; Critikon, Tampa, FL) at three different time points after short rests
with the participant seated. Blood pressure measurements were based on the mean of the
second and third measurements.
D. Statistical Analysis
Descriptive analyses comparing the distribution of cardiovascular risk factors by sex were
conducted using Pearson x2 statistic for categorical variables and Student t test for normally
distributed variables. A Wilcoxon rank sum test was used to test the distribution of non-
normally distributed variables across sexes. Deviations from normality were assessed vi-
sually by boxplots and statistically by the Shapiro-Wilk test. Partial Spearman correlation
coefficients, adjusted for age and sex, were estimated between DHEAS concentration (mg/dL)
and continuous cardiovascular risk factors.
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Candidate cardiovascular risk factors included age (years), sex, history of heart disease
(yes/no) and diabetes (yes/no), SBP (mmHg), DBP (mmHg), total cholesterol (mg/dL), HDL-C
(mg/dL), TGs (mg/dL), glucose (mg/dL), and CRP (mg/L). Cardiovascular risk factors asso-
ciated with DHEAS concentration (mg/dL; dependent variable) were identified using auto-
mated stepwise linear regressionwith an entry criterion of a = 0.20 and an exit criterion of a =
0.10, with the forced inclusion of age and sex [25]. For the linear regression analysis, DHEAS
(mg/dL), glucose (mg/dL), and TG (mg/dL) concentrations were log transformed to achieve
normality because of their highly skewed distributions. The associations between each of the
selected cardiovascular risk factors and DHEAS concentration were modeled using robust
multivariable linear regression models, which provide estimates resistant to outliers.
Three nested multivariable models, adjusted for groups of related potential confounders
and intermediates and selected on the basis of prior well-established research, were esti-
mated in the total population and separately by sex. Model 1 was mutually adjusted for the
candidate predictors identified by the stepwise regression modeling procedure, using the
entry and exit criteria previously described. Model 2, the primary model, was additionally
adjusted for potential confounders related to lifestyle/behavioral factors: smoking status
(never, former, current), alcohol consumption (g/d), physical activity metabolic equivalents
per week, and postmenopausal hormone use among women (yes/no). Model 3 further in-
cluded history of chronic disease and inflammation [history of diabetes (yes/no), body mass
index (BMI; kg/m2), antihypertensive medication use (yes/no), lipid-lowering medication use
(yes/no), SBP (mm Hg), and CRP (mg/L)]. Parameter estimates (b) with robust SE and 95%
CIs were presented (robust regression modeling allows for estimates robust to extreme
observations and modeling assumptions [22]).
On the basis of prior research, we hypothesized a priori that DHEAS concentration differed
significantly by sex, being higher among men than among women. Therefore, we proposed to
evaluate the effect modification of cardiovascular risk factors and DHEAS concentration by
sex. Significance of the interaction was assessed using aWald test statistic for the interaction
term. Analyses were restricted to participants with full data for all covariates; how-
ever, ,10% of observations were missing data on any one covariate, thus eliminating
missingness as a source of confounding in our analyses. The covariates with the greatest
missingness were SBP and DBP, with 2% missing data. All P values were two-sided with a =
0.05. Analyses were conducted with SAS (version 9.2; SAS Institute, Cary, NC).
E. Statement of Ethics
This study was approved by the institutional review boards of Tufts Medical Center and
Northeastern University, and all procedures followed were in accordance with institutional
guidelines. Participants provided written informed consent to participate [19].
2. Results
Among the 1355 participants with full covariate data, themean age was 57 years in bothmen
and women. As expected, DHEAS concentration varied by sex, with median concentration
lower among women than among men (Table 1). Moreover, the distribution of cardiovascular
risk factors also varied significantly by sex (Table 1). Women exhibited higher BMI, total
cholesterol and HDL-C levels, and CRP concentration .3 mg/L (P , 0.001) than men. Men
displayed higher SBP and DBP levels (P , 0.01) and were more likely to report current
smoking than were women (P, 0.001). Partial Spearman correlations adjusted for age and sex
showed positive linear associations between DHEAS concentration and total cholesterol level,
low-density lipoprotein level, physical activity, and alcohol consumption (P, 0.05) (Table 2). In
contrast, DHEAS concentration was inversely correlated with insulin and BMI (P , 0.01).
In univariate analyses, DHEAS concentration varied significantly across cardiovas-
cular risk factors in both men and women (Fig. 1). Among men, median concentration of
DHEAS did not vary significantly across CVD risk factors, with one exception. Themedian
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concentration of DHEAS amongmenwith total cholesterol level$200mg/dL (115 mg/dL) was
significantly higher than in thosewith total cholesterol level,200mg/dL (89mg/dL;P = 0.01).
In contrast, among women, median DHEAS concentration varied significantly across hy-
pertension status and history of CVD. Median DHEAS concentration was higher among
women without hypertension (69 mg/dL) than among those with hypertension (54 mg/dL) and
among women who did not report a history of CVD (61 mg/dL) than among those who did
(46 mg/dL; P , 0.001 for both comparisons).
Stepwise linear regression was used to identify cardiovascular risk factors that were
independently associated with DHEAS concentration. After the forced inclusion of age and
female sex, total cholesterol, high-density lipoprotein, TG, and glucose levels were selected as
cardiovascular risk factors associated with DHEAS concentration for inclusion in the final
multivariable models (P , 0.1). As expected, in sex-combined analyses using multivariable
robust linear regression, age and female sex exhibited strong inverse associations with
DHEAS concentration in all multivariable models (Table 3). When mutually adjusted for all
Table 1. Distribution of Cardiovascular Disease Risk Factors in Puerto Rican Adults by Sex
Characteristics Overall Males Females P Value
n = 1355 n = 400 n = 955
Age, y 57.0 6 7.5
[56.0 (51.0–62.0)]
56.5 6 7.8
[56.0 (51.0–62.0)]
57.1 6 7.4
[56.0 (51.0–62.0)]
0.16a
DHEAS(mg/dL) 84.6 6 67.9
[68.0 (39.0–111.0)]
117.0 6 84.4
[99.5 (59.0–154.5)]
71.1 6 54.3
[58.0 (34.0–94.0)]
,0.001b
CVD risk factors
BMI, kg/m2 31.7 6 6.4
[30.9 (27.3–35.2)]
29.6 6 5.3
[29.2 (26.2–33.0)]
32.5 6 6.7
[31.8 (28.0–36.5)]
,0.001a
Systolic blood
pressure, mm Hg
135.0 6 19.2
[133.3 (121.3–146.0)]
137.4 6 19.1
[135.6 (124.9–148.3)]
134.0 6 19.2
[132.5 (119.8–145.5)]
0.003a
Diastolic blood
pressure, mm Hg
81.1 6 10.7
[80.5 (73.5–87.8)]
83.0 6 11.1
[82.4 (75.3–89.0)]
80.2 6 10.4
[79.8 (73.0–87.0)]
,0.001a
Total cholesterol, mg/dL 184.4 6 41.8
[182.0 (154.0–212.0)]
173.9 6 43.0
[172.0 (143.0–202.0)]
188.8 6 40.5
[188.0 (159.0–216.0)]
,0.001a
HDL-C, mg/dL 45.1 6 12.5
[43.0 (37.0–51.0]
40.5 6 12.3
[38.0 (32.0–47.0)]
47.1 6 12.1
[45.0 (39.0–53.0)]
,0.001b
Triglycerides, mg/dL 163.2 6 114.4
[136.0 (100.0–191.0)]
175.5 6 143.2
[144.0 (98.5–202.5)]
158.0 6 99.5
[134.0 (100.0–185.0)]
0.12b
Fasting plasma
glucose, mg/dL
119.4 6 50.8
[102.0 (92.0–127.0)]
121.2 6 53.7
[102.0 (92.0–129.0)]
118.6 6 49.5
[102.0 (992.0–126.0)]
0.72b
HbA1c $6, % 70.6 67.5 71.7 0.14
c
CRP $3, mg/L, % 56.3 42.8 62.0 ,0.0001c
History of CVD, % 20.4 22.5 19.6 0.22c
Hypertension, %d 67.5 68.8 66.9 0.51c
Diabetes, % 38.5 40.3 37.8 0.40c
Antihypertensive
medication, %
58.8 58.8 58.7 .0.99c
Lipid-lowering
medication, %
40.2 38.8 40.7 0.50c
Lifestyle factors
Current smoker, % 24.7 33.3 21.1 ,0.0001c
Alcohol, g/d 1.5 6 0.6
[1.0 (1.0–2.0)]
1.7 6 0.7
[2.0 (1.0–2.0)]
1.4 6 0.6
[1.0 (1.0–2.0)]
,0.0001b
Physical activity,
METs/wk
31.6 6 4.0
[30.2 (28.2–33.0)]
32.5 6 5.7
[31.1 (28.6–32.1)]
31.2 6 4.0
[30.2 (28.3–33.0)]
0.001b
Values are means 6 SD, [medians (IQR)], or percentages.
Abbreviation: METs/wk, metabolic equivalents per week.
aP value based on two independent sample t tests.
bP value based on Wilcoxon rank sum test.
cP value based on x2 test.
dBased on values or antihypertensive medication use.
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predictors (model 1), DHEAS concentration was 1.9% (95% CI: 0.7, 3.1) higher with each
10-mg/dL increase in total cholesterol level and 0.2% (95% CI: 0.03, 0.3) higher with each 10%
increase in glucose level. In contrast, a 0.2% lower DHEAS concentration (95% CI:
20.3, 20.1) was seen with each 10% increase in TG level. Estimates were modestly at-
tenuated toward the null after adjustment for potential lifestyle/behavioral confounders
(model 2). After adjustments for potential history of chronic disease and inflammation (model
3), glucose level was no longer significantly associated with DHEAS concentration.
Evidence suggests that the association between cardiovascular risk factors and DHEAS
concentration may vary by sex (Pinteraction , 0.05) (Table 3). Age was associated with sig-
nificantly lower DHEAS concentration among women than among men (14.7% vs 6.9%, per
5-year increase; Pinteraction = 0.02). Glucose level was associated with significantly greater
DHEAS concentration (mg/dL) among women but not among men (Pinteraction = 0.03).
3. Discussion
In this unique study in a large sample of Latinos at high risk of CVD, serum DHEAS levels
exhibited significant associations with age, sex, and lipid and glucose concentrations. As
expected, the strongest associations were observed with age and sex. We observed para-
doxical support for the role of DHEAS in cardiovascular risk. Significant associations be-
tween plasma lipids, glucose, and serum DHEAS levels were independent of potential
confounders, history of chronic CVD, and inflammation. However, the direction of the as-
sociations varied across cardiovascular risk factors and by sex. Specifically, higher DHEAS
concentration was associated with higher total cholesterol concentration among men,
whereas higher DHEAS concentration was associated with higher glucose concentration
amongwomen. In contrast, higherDHEAS concentration was associatedwith lower TG levels
among both men and women. Hence, the role of DHEAS in cardiovascular risk remains
uncertain because of these paradoxical and conflicting associations across cardiovascular
risk factors.
Whether DHEAS concentration is influenced by race/ethnicity is uncertain because of a
paucity of adrenal hormonal data available for racial/ethnic minorities [6‒9]. Some studies
have reported lower DHEAS concentrations among black women [8] and Japanese men [26]
compared with their non-Hispanic white counterparts, whereas others have reported null
findings [6, 7, 9]. Only two studies included Latinos, and both failed to find significant
variation by race/ethnicity; however, specific information regarding heritage backgroundwas
not provided [6, 7]. Of note, the distribution of DHEAS concentration in this study was similar
to that reported by others with similarly aged populations [11, 27].
Table 2. Partial Spearman Correlations Between DHEAS Concentration (mg/dL) and Cardiovascular
Risk Factors
ra P Value
Age, y 20.25 ,0.0001
Systolic blood pressure, mm Hg 0.03 0.31
Diastolic blood pressure, mm Hg 0.03 0.32
Cholesterol, mg/dL 0.07 0.02
HDL, mg/dL 0.02 0.43
Triglycerides, mg/dL 20.05 0.05
CRP, mg/L 0.03 0.34
Fasting glucose, mg/dL 0.05 0.06
HbA1c% 0.01 0.81
BMI, kg/m2 20.08 0.01
Physical activity, METs/wk 0.07 0.01
Alcohol, g/d 0.11 0.0001
Abbreviations: HDL, high-density lipoprotein; METs/wk, metabolic equivalents per week.
aPartial Spearman correlation coefficient adjusted for age and sex, except for age, which is adjusted only by sex.
296 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00205
DHEAS exhibited a stronger age-related decline among women than among men, which
raises questions about whether DHEAS may be more strongly related to female than to male
cardiovascular health. Although it is well established that DHEAS concentration declines
with age, it is less understood whether age-related declines vary by sex. We observed a
stronger inverse association between DHEAS concentration and age among women than
among men (Pinteraction = 0.02), consistent with reports in short-term follow-up studies of
change in DHEAS concentration by sex [27]. However, no differences by sex were reported in
another study tracking individuals over 5 years [28]. Therefore, our results may simply
reflect a lower baseline concentration of DHEAS among women.
The overall findings in this study contrasted with previouswork in both animal and human
models, which supports potential mechanisms by which DHEAS concentrationmay influence
the pathogenesis of CVD through cardiovascular risk factors. Previous studies suggested that
Figure 1. Sex-specific differences in median DHEAS concentration (mg/dL) by cardiovascular
risk factors. Median DHEAS concentration for men is presented by solid bars and for women
by dotted bars. Bars reflect bounds of 95% CI. P values are for sex-specific differences in
median DHEAS concentration between the presence or absence of specified cardiovascular
risk factors. *P , 0.001; †P = 0.01. HTN, hypertension; TC, total cholesterol.
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DHEAS may act through atherosclerotic-related mechanisms, such as inhibiting the mi-
gration and proliferation of cells within the vascular wall and increasing vascular smooth
muscle cell apoptosis, thereby reducing vascular remodeling after injury [29]. Moreover,
DHEAS has been suggested to improve insulin resistance through reduced hepatocyte glucose
production [12] and improved peripheral tissue glucose clearance. However, our findings do not
support an inverse association between DHEAS and glucose concentrations [13]. Of note, it
remains uncertain whether DHEAS acts alone or predominantly through conversion to
estrogens/androgens. Moreover, although DHEAS can act independently in many cell types,
including vascular endothelium cells [30], its androgenic/estrogenic activitymay vary given the
underlying hormonal environment [31]. Hence, apparent inconsistencies between DHEAS and
cardiovascular risk factors by sex may be partially explained by hormonal differences.
In addition, it is unclear whether our disparate findings were influenced by the heavy
burden of cardiovascular risk factors in this population, leading to potential differences in
DHEAS activity. In fact, when median DHEAS concentrations were compared across the
cardiovascular risk factor profile (Fig. 1), median DHEAS concentration was higher among
those without a history of hypertension, CVD, or diabetes or a BMI $30 kg/m2 than among
those with these CVD risk factors; however, differences in median DHEAS concentration
were significant among women only for hypertension and history of CVD. Hence, further
work is needed to explore these findings in other populations.
Previous studies reported inconsistent findings with respect to the association between
plasma lipids and serum DHEAS levels. We have limited our discussion to the few studies
that used multivariable methods, noting that all have been conducted among postmenopausal
women, limiting generalizability to men [15, 17, 18]. No multivariable associations between
total cholesterol and DHEAS levels were reported among samples of middle-aged post-
menopausal women from theMassachusettsWomen’sHealth Study [15] or the Atherosclerosis
Table 3. Multivariable Associations Between Cardiovascular Risk Factors and DHEAS (mg/dL)
Cardiovascular Risk Factors Model 1 Model 2 Model 3
Total b (95% CI) b (95% CI) b (95% CI)
Age, ya 213.9 (216.6, 211.2) 212.4 (215.2, 29.7) 212.9 (215.9, 29.9)
Female sexb 251.3 (260.4, 242.3) 246.0 (255.3, 236.6) 243.7 (253.3, 234.2)
Cholesterol, mg/dLc 1.9 (0.7, 3.1) 1.8 (0.6, 3) 1.6 (0.4, 2.8)
HDL, mg/dL 20.2 (20.6, 0.2) 20.3 (20.2, 0.7) 20.4 (20.8, 0.04)
Triglycerides, mg/dLd 20.2 (20.3, 20.1) 20.2 (20.3 20.1) 20.2 (20.3, 20.1)
Glucose, mg/dLd 0.2 (0.03, 0.3) 0.2 (0.04, 0.3) 0.2 (20.02, 0.3)
Sex Stratified Mene Womene P Sex Interaction
Age, ya 26.9 (211.7, 22.1) 214.7 (218.1, 211.4) 0.02
Cholesterol, mg/dLc 3.2 (1.0, 5.3) 1.2 (20.2, 3.6) 0.17
HDL, mg/dL 0.2 (20.6, 1.0) 20.6 (21.1, 20.1) 0.15
Triglycerides, mg/dLc 20.1 (20.3, 0.1) 20.2 (20.3, 20.1) 0.25
Glucose, mg/dLc 20.04 (20.3, 0.2) 0.3 (0.1, 0.4) 0.03
Multivariable analyses were conducted using robust linear regression between selected cardiovascular risk factors
and DHEAS. DHEAS, triglycerides, and glucose levels were log transformed to achieve normality. Model 1 mutually
adjusted for all selected predictors. Model 2: Model 1 + smoking, alcohol, physical activity, and among women
postmenopausal hormone use.Model 3:Model 2 + diabetes status, history of cardiovascular disease, bodymass index,
antihypertensive medication use, lipid-loweringmedication use, systolic blood pressure, and C-reactive protein. Bold
face indicates results are statistically significant a = 0.05.
Abbreviation: HDL, high-density lipoprotein.
aPercentage change in DHEAS per 5-year increase in age.
bPercentage change in DHEAS per unit increase in predictor (e.g., women compared with men).
cPercentage change in DHEAS per 10 mg/dL increase in total cholesterol.
dPercentage change in DHEAS per 10% change in each predictor.
eSex-specific models adjusted for covariates in Model 2.
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Risk in Communities Study [18]. It is worth noting that our results showed some consistency
with these findings. Although the interaction with sex for total cholesterol and DHEAS levels
was not statistically significant (Pinteraction = 0.17), stratified analysis showed significantly
higher DHEAS concentration with higher total cholesterol concentration among men (b = 3.2;
95% CI: 1.0, 5.3) but not among women (b = 1.2; 95% CI: 20.2, 3.6). DHEAS is derived from
cholesterol; therefore, the overall positive association observed with total cholesterol may be
due to DHEAS biosynthesis. Our findings for TGs were similar to those demonstrated by Bell
et al. [32], who reported lower DHEAS concentration with higher TG levels when adjusted for
age, BMI, smoking, alcohol, and exercise among a population-based sample of postmenopausal
Australian women. Our data provide initial multivariable-adjusted results for an association
between TGs and DHEAS concentration among men.
Several small randomized trials demonstrated that dehydroepiandrosterone (DHEA)
supplementation lowered glucose concentration or improved insulin sensitivity through
glucose stabilization and improved insulin action [33‒35], but others have been null [36‒38]
or have indicated that higher DHEAS concentration may be associated with hyper-
insulinemia [39]. All have been limited by small sample size, short follow-up, or highly
specific populations, such as the elderly or those with adrenal hormone deficiencies [33‒36,
38]. We found that higher glucose level was associated with higher DHEAS concentration and
observed that the association may be restricted to women (Pinteraction = 0.03). Similarly, in a
multiethnic population of postmenopausal women, those in the highest quartile of DHEAS
concentration had 68% greater odds of impaired fasting glucose level than women in the
lowest quartile (OR = 1.68; 95% CI: 1.23, 2.29; P trend , 0.001) when adjusted for age, race/
ethnicity, and study site [40]. Estimates remained elevated, but were no longer significant,
after adjustment for lifestyle and behavioral confounders (OR = 1.43; 95% CI: 0.97, 2.13; P
trend = 0.02).
The discrepancy of these findingsmay be due to variation in insulin resistance; Farah et al.
[41] demonstrated that insulin resistance was associated with increased production of
DHEAS, which may partially explain our findings, given the high burden of diabetes and
overweight/obesity in this study population. Moreover, the association between DHEAS
concentration and adiposity has been inconsistent, with studies reporting null, positive, and
inverse associations [2, 42‒44]. Although a weak inverse correlation was observed between
BMI andDHEAS in our study, BMI was not identified as a significant explanatory variable of
DHEAS in multivariable models. This may suggest that DHEAS is more closely associated
with mechanisms of metabolic regulation through pathways other than obesity.
Furthermore, chance findings associated with evaluation of multiple subgroups in our
analyses may also explain the apparent heterogeneity. Further investigation is needed to
examine these findings and sex differences in the association between DHEAS and glucose
levels across other populations.
It is important to note that we did not observe multivariable associations between SBP or
DBP and DHEAS levels, as previously reported in observational cohorts [11, 15]. However,
our findings are consistent with those of a randomized controlled trial of DHEA supple-
mentation among frail elderly patients, which failed to show significant associations with
either SBP or DBP level [45]. Data from observational cohorts have generally involved
populations with considerably healthier cardiovascular profiles than those in the current
study or the aforementioned trial of DHEA supplementation; hence, comorbid conditions or
medication use could mask an underlying association with blood pressure.
This study has several strengths and limitations. Important strengths include the large
sample size of Latinos, interviewer-administered questionnaires, and clinically assessed bio-
markers. DHEAS is a more stable marker than DHEA, given a longer half-life, and it does not
exhibit a strong diurnal variation, which is further attenuated or even lost with increasing age
[14, 46‒48]. However, it should be noted that samples were collected in the morning, which does
not correspond with the acrophase of the 24-hour circadian cycle of DHEAS, which is noted to
occur in the late afternoon (approximately 16:00) and to be of small amplitude [46, 47, 49]. Given
the age distribution of our population, the timing of blood collection is unlikely to result in
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systematic bias, and a single measure of DHEAS is expected to reasonably reflect the mesor [46,
47]. In addition, we appreciate potential concerns regarding multiple testing; however, adjusted
type I error would result in inflated type II error and a greater risk of failing to observe key
biologic associations for future investigation [50]. These data provide evidence suggesting that
DHEAS may influence cardiovascular risk through lipid and glucose mechanisms; however, it
remains uncertain whether DHEAS plays a direct role in the etiologic pathogenesis of car-
diovascular risk or serves as a sensitivemarker of subclinical vascular disease. Therefore, further
studies with longitudinal measures of DHEAS and cardiovascular risk factors are needed.
This study reportedDHEAS concentrations across cardiovascular risk factors among Puerto
Rican adults. However, generalizability of these results to other racial/ethnic and socio-
demographic groups may be limited. Moreover, given the cross-sectional nature of the study,
the temporality of the associations cannot be identified. It has been proposed that changes in
DHEAS concentration over time may be a stronger predictor of cardiovascular mortality than
baseline concentration; whether this is consistent with changes in cardiovascular risk factors
could not be explored in the current analysis and requires further investigation.
4. Conclusions
This study in an understudied minority group with a high burden of cardiovascular risk
factors provides evidence to support the association between DHEAS and key cardiovascular
risk factors, primarily lipid and glucose levels. However, the role of DHEAS in influencing
cardiovascular risk may be influenced by an individual’s underlying cardiovascular risk
burden, in some cases leading to seemingly paradoxical results. These findings may inform
future research and eventually interventions in this and other high-risk populations.
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